Family Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Family Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,250	Closed	-$241K	–	72
2017 Q2	$241K	Hold	7,250	–	–	0.17%	50
2017 Q1	$233K	Hold	7,250	–	–	0.16%	53
2016 Q4	$263K	Hold	7,250	–	–	0.18%	53
2016 Q3	$334K	Hold	7,250	–	–	0.19%	57
2016 Q2	$364K	Hold	7,250	–	–	0.21%	56
2016 Q1	$388K	Hold	7,250	–	–	0.25%	45
2015 Q4	$476K	Hold	7,250	–	–	0.25%	50
2015 Q3	$409K	Hold	7,250	–	–	0.18%	64
2015 Q2	$428K	Hold	7,250	–	–	0.18%	62
2015 Q1	$452K	Hold	7,250	–	–	0.21%	59
2014 Q4	$417K	Hold	7,250	–	–	0.19%	62
2014 Q3	$390K	Hold	7,250	–	–	0.18%	61
2014 Q2	$380K	Hold	7,250	–	–	0.19%	57
2014 Q1	$383K	Hold	7,250	–	–	0.2%	53
2013 Q4	$291K	Hold	7,250	–	–	0.17%	53
2013 Q3	$274K	Hold	7,250	–	–	0.18%	51
2013 Q2	$284K	Buy	+7,250	New	+$282K	0.17%	65

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Family Management's TEVA Position: Q3 2017 in Review

Family Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 7,250 shares — an estimated $241K sold.

Family Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $476K in Q4 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Family Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
Family Management sold 7,250 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $241K.
Family Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 17 quarters.
Family Management's Teva Pharmaceutical Industries Limited position peaked at $476K in Q4 2015.
537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Family Management's 13F filing for Q3 2017, filed 13 Nov 2017.